---

Who We Are                                            

Urigen Pharmaceuticals' leadership is comprised of industry-leading management and world-renowned scientific advisors. Our team has decades of experience in Pharma business, commercial and product development. Collectively, we have planned and executed studies on numerous marketed and development compounds and our management did pioneering work in the field o f IC/BPS.

 

Dan Vickery, PhD, MBA

Director, COO and President Urigen Pharmaceuticals

Dr. Vickery’s experience includes senior corporate business and commercial development positions at Mylan Pharmaceuticals, Inc., and Pharmacia, Inc., and senior regulatory affairs positions at Kabi Pharmacia, Inc., and Warner-Lambert Inc. Dr. Vickery is an advisory board member of the Center for Molecular Medicine and Therapeutics, and on the Board of the Interstitial Cystitis Association. Dr. Vickery holds B.Sc. and Ph.D. degrees from the University of British Columbia, and earned an M.B.A. degree from the Richard Ivey School of Business, University of Western Ontario.

---

Lowell Parsons, MD

Chairman and Scientific Founder Urigen Pharmaceuticals

Dr. Parsons is a leader in medical research into the causes and treatment of interstitial cystitis, which is a BPS with typical cystoscopic and/or histological features in the absence of infection or other pathology, and has published over 200 scientific articles and book chapters in this area describing his work. Dr. Parsons received his M.D. degree from the Yale University School of Medicine in New Haven, CT, in 1970. After completing his medical internship at Yale in 1971, Dr. Parsons spent two years as a staff associate in the Laboratory of Microbiology at the National Institutes of Health in Bethesda, Maryland. He then completed his urology residency training at the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, in 1977. Dr. Parsons joined the Division of Urology faculty at the University of California, San Diego, or UCSD, in 1977 as assistant professor. He served as Chief of Urology at the UCSD-affiliated Veterans Affairs Medical Center in La Jolla from 1977 to 1985. Since 1988, he has been Professor of Surgery/Urology at UCSD.

---

Robert Evans, MD

Director

Dr. Evans is a leading IC/BPS Urologist and holds a dual Professor appointment in both the departments of Urology and Gynecology, and he is the Director of Outpatient Clinical Operations for the department of Urology at Wake Forest University Baptist Medical Center in Winston Salem NC. He is also a Senior Associate at the Wake Forest Institute for Regenerative Medicine (FIRM), for Wake Forest. He is an NIH funded researcher into genetic causes for IC/BPS, finding biomarkers and subgroups for IC/BPS to develop focused therapies, and he is also a member of the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. His additional board experience includes the Medical Advisory Board of the Interstitial Cystitis Association (ICA) and of the IC Network, a and as a board member for a private technology company Space Express Corporation. He has been voted best IC doctor in the world 4 years in a row for the IC Network, and he has previously commercialized a technology for male infertility. Prior to Wake Forest he served as the Chief of Surgery for the Moses Cone Health System. He received his MD from Jefferson Medical College and did Residency and graduate training at the University of Virginia.

---

Carlo J. Di Fonzo, PhD

Director

Dr. Di Fonzo leads drug development and regulatory affairs at Nektar with oversight responsibilities for regulatory affairs, GCP/GLP compliance and toxicology. Dr. Di Fonzo's experience includes over 25 years in regulatory affairs and safety roles in the pharmaceutical and biotechnology industry. During his career, Dr. Di Fonzo has been part of several teams that helped bring new medicines to patients, including Lipitor®, Neurontin®, Accupril®, Xigris®, Forteo®, Alimta®, Gemzar®, Zyprexa®, Strattera®, Cialis® and Movantik™. Prior to joining Nektar in 2006, Dr. Di Fonzo led regulatory affairs and quality compliance at Eli Lilly Canada, where he was also responsible for patent-listing strategies and product safety functions. Prior to joining Eli Lilly in November 2000, he worked at Warner-Lambert/Parke-Davis Canada, where he was had oversight of toxicology and safety studies as well as regulatory affairs. Dr. Di Fonzo received his undergraduate degree in biologic sciences, his master's degree in clinical biochemistry and his Ph.D. in clinical biochemistry and toxicology from the University of Toronto, Canada.